ERBB2 and breast cancer: FMD regimen has been reported to reduce the negative side-effects of chemotherapy in post-menopausal women with HER2-negative stage II/III breast cancer, although the impact of FMD in the absence of chemotherapy could not be assessed on ethical grounds15.